303 related articles for article (PubMed ID: 31200515)
1. Telomerase and Telomeres Biology in Thyroid Cancer.
Donati B; Ciarrocchi A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200515
[TBL] [Abstract][Full Text] [Related]
2. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):515-525. PubMed ID: 32981294
[TBL] [Abstract][Full Text] [Related]
4. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
5. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract][Full Text] [Related]
6. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
8. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
12. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations in thyroid cancer.
Matsuse M; Mitsutake N
Endocr J; 2023 Nov; 70(11):1035-1049. PubMed ID: 37532521
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
[TBL] [Abstract][Full Text] [Related]
17. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.
Wang N; Xu D; Sofiadis A; Höög A; Vukojević V; Bäckdahl M; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1571-9. PubMed ID: 24758186
[TBL] [Abstract][Full Text] [Related]
18. Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects.
Landa I; Thornton CEM; Xu B; Haase J; Krishnamoorthy GP; Hao J; Knauf JA; Herbert ZT; Martínez P; Blasco MA; Ghossein R; Fagin JA
Mol Cancer Res; 2023 Nov; 21(11):1163-1175. PubMed ID: 37478162
[TBL] [Abstract][Full Text] [Related]
19. Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.
McKelvey BA; Umbricht CB; Zeiger MA
Front Endocrinol (Lausanne); 2020; 11():485. PubMed ID: 32849278
[No Abstract] [Full Text] [Related]
20. Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.
Yuan X; Liu T; Xu D
Ann Transl Med; 2020 Oct; 8(19):1244. PubMed ID: 33178776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]